Patents by Inventor Ariane CAESAR

Ariane CAESAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220003789
    Abstract: A device for determining a cellular-bound analyte in a liquid sample includes a separation matrix with at least one indicator zone. The indicator zone includes a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody. The first antibody is an incomplete antibody. The separation matrix can be designed in the form of the membrane of a lateral flow assay device or as a gel matrix. For example, the device can include a membrane with a charging zone for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region, which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone and the absorption region. The indicator zone can include an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Inventors: Peter SCHWIND, Ariane CAESAR
  • Patent number: 11169160
    Abstract: The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3).
    Type: Grant
    Filed: May 23, 2015
    Date of Patent: November 9, 2021
    Assignee: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: Peter Schwind, Ariane Caesar
  • Publication number: 20170122968
    Abstract: The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3).
    Type: Application
    Filed: May 23, 2015
    Publication date: May 4, 2017
    Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC
    Inventors: Peter SCHWIND, Ariane CAESAR